

HER2 Positive Breast Cancer PDX Models




WuXi AppTec Research Service Division, Oncology & Immunology Unit




2019.09

- Breast cancer is the most frequently diagnosed cancer globally and is the leading cause of cancer-related death in woman.
- A central component of the treatment of breast cancer is full knowledge of extent of disease and biologic features. These factors are determined by examination of excised tissue and are provided in a written pathology report.
- The college of American Pathologists (CAP) has developed pathology reporting protocols to promote complete and standardized reporting of malignant specimens. The checklists are available through the CAP website at www.cap.org.

Estimated number of new cases in 2018, China, all cancers, females, all ages




Estimated number of deaths in 2018, China, all cancers, females, all ages



HER2 IHC analysis

Recommendations for HER2 Testing in Breast Cancer.










HER2 targeted PDX models

Model ID	Cancer type	Pathology diagnosis (PDX)	Treatment	TGI (%)
BR-05-0168	Breast cancer	Her2 positive	Herceptin 5 mg/kg , i.v., BIW	61
BR-05-0434	Breast cancer	Her2 positive	Herceptin 5 mg/kg , i.v., BIW	9.6
BR-05-0452E	Breast cancer	Her2 positive	Herceptin 5 mg/kg , i.v., BIW	76.1



BR-05-0168 Growth Curves

Model ID	Cancer Type	Pathology diagnosis (clinic)	Pathology diagnosis (PDX)	Gender	Age	Tumor Grade	Tumor Stage
BR-05-0168	Breast Cancer	ER (-),PR (1-3%+),c-erbB-2(2+)	ER>1%, PR(-), HER-2(+)	Female	35	III	II





Herceptin in BR-05-0168 Breast cancer PDX Model




Animal	Estradiol	Tumor inoculation	Latent Period (Days)
NOD-SCID Female (LC)	-	20-30mm ³	80

Note : D0-D7 QW; D10-D42 BIW


BR-05-0434_Growth Curves

Model ID	Cancer Type	Pathology diagnosis	Pathology diagnosis (PDX)	Gender	Age	Tumor Grade	Tumor Stage
BR-05-0434	Breast cancer	ER(-), PR(-), HER2(in situ+, infiltrating 3+)	HER2 positive	Female	41	High grade	NA


BR-05-0434 P0




BR-05-0434E P1





BR-05-0434 P2





BR-05-0434 P3








Herceptin in BR-05-0434 Breast Cancer PDX Model





Animal	Estradiol	Tumor inoculation	Latent Period (Days)
NOD-SCID Female	-	20-30mm ³	38



BR-05-0452E_Growth Curves

Model ID	Cancer Type	Pathology diagnosis (clinic)	Pathology diagnosis (PDX)	Gender	Age	Tumor Grade	Tumor Stage
BR-05-0452	Breast Cancer	ER(-), PR(-), HER2(3+)	HER2 positive	Female	NA	III	NA











Herceptin in BR-05-0452E Breast Cancer PDX Model



Animal	Estradiol	Tumor inoculation	Latent Period (Days)
NOD-SCID Female	+	20-30mm ³	30

Negative/positive controls for IHC





OUR COMMITMENT

Improving Health. Making a Difference.

For questions and requests, please email to info_onco@wuxiapptec.com



<https://onco.wuxiapptec.com>



Mobile App